Last reviewed · How we verify

Crenessity — Competitive Intelligence Brief

Crenessity (CRINECERFONT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]. Area: Nephrology.

marketed Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC] Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Crenessity (CRINECERFONT) — Neurocrine. Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Crenessity TARGET CRINECERFONT Neurocrine marketed Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC] class)

  1. Neurocrine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Crenessity — Competitive Intelligence Brief. https://druglandscape.com/ci/crinecerfont. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: